MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications.
Flawless balance sheet and undervalued.
- MediWound has significant price volatility in the past 3 months.
Share Price & News
How has MediWound's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
1 Year Return
MDWD underperformed the Pharmaceuticals industry which returned -6.6% over the past year.
MDWD underperformed the Market in United States of America which returned -0.4% over the past year.
Share holder returns
Price Volatility Vs. Market
How volatile is MediWound's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall StMediWound Ltd. (NASDAQ:MDWD): Commentary On Fundamentals
1 month ago | Simply Wall StIntroducing MediWound (NASDAQ:MDWD), The Stock That Tanked 72%
2 months ago | Simply Wall StWhat Percentage Of MediWound Ltd. (NASDAQ:MDWD) Shares Do Insiders Own?
Is MediWound undervalued based on future cash flows and its price relative to the stock market?
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
MediWound's share price is below the future cash flow value, and at a moderate discount (> 20%).
MediWound's share price is below the future cash flow value, and at a substantial discount (> 40%).
Price Based on Earnings
MediWound is good value based on earnings compared to the US Pharmaceuticals industry average.
MediWound is good value based on earnings compared to the United States of America market.
Price Based on Expected Growth
MediWound is good value based on expected growth next year.
Price Based on Value of Assets
MediWound is overvalued based on assets compared to the US Pharmaceuticals industry average.
How is MediWound expected to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
MediWound's revenue is expected to grow significantly at over 20% yearly.
MediWound's earnings are expected to grow significantly at over 20% yearly.
MediWound's revenue growth is expected to exceed the United States of America market average.
MediWound's earnings growth is expected to exceed the United States of America market average.
MediWound's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if MediWound will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
How has MediWound performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
MediWound's year on year earnings growth rate has been positive over the past 5 years.
MediWound has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
MediWound has become profitable in the last year making it difficult to compare the US Pharmaceuticals industry average.
Return on Equity
MediWound made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).
Return on Assets
MediWound used its assets more efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.
Return on Capital Employed
MediWound has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
How is MediWound's financial position?
Financial Position Analysis
MediWound is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
MediWound's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
MediWound has no debt.
MediWound currently has no debt however we can't compare to 5 years ago as we have no data for that period.
MediWound has no debt, it does not need to be covered by operating cash flow.
MediWound has no debt, therefore coverage of interest payments is not a concern.
Low level of unsold assets.
MediWound has no debt, it does not need to be covered by short term assets.
What is MediWound's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate MediWound's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate MediWound's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as MediWound has not reported any payouts.
Unable to verify if MediWound's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as MediWound has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
What is the CEO of MediWound's salary, the management and board of directors tenure and is there insider trading?
Average management tenure
Sharon Malka (47yo)
Mr. Sharon Malka, C.P.A., MBA, has been the Chief Financial & Operation Officer at MediWound Ltd. since April 2007 and serves as its Chief Executive officer since May 31, 2019. Mr. Malka served as a Partne ...
CEO Compensation Analysis
Sharon's remuneration is about average for companies of similar size in United States of America.
Sharon's compensation has been consistent with company performance over the past year, both up more than 20%.
Management Age and Tenure
The average tenure for the MediWound management team is over 5 years, this suggests they are a seasoned and experienced team.
Board Age and Tenure
The average tenure for the MediWound board of directors is less than 3 years, this suggests a new board.
No 3 month open market individual insider trading information.
Lior Rosenberg (73yo)
Co-Founder & Chief Medical Technology Officer
- Tenure: 18.6yrs
- Compensation: $148.49k
Sharon Malka (47yo)
Chief Executive Officer
- Tenure: 0.3yrs
- Compensation: $412.30k
Yaron Meyer (40yo)
General Counsel & Corporate Secretary
- Tenure: 5.7yrs
- Compensation: $531.88k
Ety Klinger (57yo)
Chief Research & Development Officer
- Tenure: 5.3yrs
- Compensation: $374.03k
Carsten Henke (53yo)
Chief Commercial Officer of Europe
- Tenure: 4.8yrs
- Compensation: $405.11k
Boaz Gur-Lavie (45yo)
Chief Financial Officer
- Tenure: 0.2yrs
Steve Wills (62yo)
Chairman of the Board of Directors
- Tenure: 1.8yrs
Nissim Mashiach (58yo)
- Tenure: 2.2yrs
Sharon Kochan (51yo)
- Tenure: 2.2yrs
Ofer Gonen (45yo)
- Tenure: 15.9yrs
Vickie Driver (65yo)
- Tenure: 2.3yrs
- Tenure: 1.8yrs
MediWound Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: MediWound Ltd.
- Ticker: MDWD
- Exchange: NasdaqGM
- Founded: 2000
- Industry: pharmaceuticals
- Sector: pharmaceuticals & biotech
- Market Cap: US$73.655m
- Shares outstanding: 27.18m
- Website: Click here
Number of Employees
- MediWound Ltd.
- 42 Hayarkon Street
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MDWD||NasdaqGM (Nasdaq Global Market)||Yes||Ordinary Shares||US||USD||Mar 2014|
|M8W||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Mar 2014|
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/08/18 00:57|
|End of Day Share Price||2019/08/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.